The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD
Open accessAbstract
AKI is associated with high morbidity and mortality, and it predisposes to the development and progression of CKD. Novel strategies that minimize AKI and halt the progression of CKD are urgently needed. Normal kidney function involves numerous different cell types, such as tubular epithelial cells, endothelial cells, and podocytes, working in concert. This delicate balance involves many energy-intensive processes. Fatty acids are the preferred energy substrates for the kidney, and defects in fatty acid oxidation and mitochondrial dysfunction are universally involved in diverse causes of AKI and CKD. This review provides an overview of ATP production and energy demands in the kidney and summarizes preclinical and clinical evidence of mitochondrial dysfunction in AKI and CKD. New therapeutic strategies targeting mitochondria protection and cellular bioenergetics are presented, with emphasis on those that have been evaluated in animal models of AKI and CKD. Targeting mitochondrial function and cellular bioenergetics upstream of cellular damage may offer advantages compared with targeting downstream inflammatory and fibrosis processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kang, H. M., Ahn, S. H., Choi, P., Ko, Y.-A., Han, S. H., Chinga, F., Park, A. S. D., Tao, J., Sharma, K., Pullman, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3762 · Cited by 1,555
Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors
Kagan, V. E., Tyurin, V. A., Jiang, J., Tyurina, Y. Y., Ritov, V. B., Amoscato, A. A., Osipov, A. N., Belikova, N. A., Kapralov, A. A., Kini, V., et al. (2005) · Nature Chemical Biology · doi:10.1038/nchembio727 · Cited by 1,256
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173
Chu, C. T., Ji, J., Dagda, R. K., Jiang, J. F., Tyurina, Y. Y., Kapralov, A. A., Tyurin, V. A., Yanamala, N., Shrivastava, I. H., Mohammadyani, D., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2837 · Cited by 1,083
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782
Self-citationMitochondrially targeted compounds and their impact on cellular bioenergetics
Reily, C., Mitchell, T., Chacko, B. K., Benavides, G. A., Murphy, M. P., & Darley-Usmar, V. M. (2013) · Redox Biology · doi:10.1016/j.redox.2012.11.009 · Cited by 227
Dare, A. J., Bolton, E. A., Pettigrew, G. J., Bradley, J. A., Saeb-Parsy, K., & Murphy, M. P. (2015) · Redox Biology · doi:10.1016/j.redox.2015.04.008 · Cited by 202
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Park, C. W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M.-T., Fan, X., Davis, L., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000209 · Cited by 202
Sohn, M., Kim, K., Uddin, M. J., Lee, G., Hwang, I., Kang, H., Kim, H., Lee, J. H., & Ha, H. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00596.2015 · Cited by 80
Cited by
Renal tubule injury: a driving force toward chronic kidney disease
Liu, B.-C., Tang, T.-T., Lv, L.-L., & Lan, H.-Y. (2018) · Kidney International · doi:10.1016/j.kint.2017.09.033 · Cited by 913
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Barriers and Advances in Kidney Preservation
Steichen, C., Giraud, S., Bon, D., Barrou, B., Badet, L., Salamé, E., Kerforne, T., Allain, G., Roumy, J., Jayle, C., et al. (2018) · BioMed Research International · doi:10.1155/2018/9206257 · Cited by 370
Chen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases
Fontecha-Barriuso, M., Martin-Sanchez, D., Martinez-Moreno, J., Monsalve, M., Ramos, A., Sanchez-Niño, M., Ruiz-Ortega, M., Ortiz, A., & Sanz, A. (2020) · Biomolecules · doi:10.3390/biom10020347 · Cited by 294
Metadata
- Authors
- Szeto, H. H.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-08-04
- Volume
- 28
- Issue
- 10
- Pages
- 2856-2865
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2743743758
- Cited by
- 199
- References
- 9
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD. https://app.cochat.ai/papers/10.1681/asn.2017030247
- The paper
- Szeto, H. H. (2017). Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2017030247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.